Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Chronic Disease Management

 

Eurocept buys Medizorg and tries to re-invent homecare

Eurocept, the Dutch pharmaceutical and home care company backed by private equity house GIMV, is to buy medicalised homecare group Medizorg to create a group with sales of €300m with Benelux and Pan-Nordic ambitions. We talk to Eurocept CEO, Mike van Woensel about homecare business models.

Public healthcare sector killing private companies in Italy

Late payments, shut downs and politically driven management – welcome to the world of Italian private healthcare operators. We talk to Sergio Antonio Bolognese at Espansione, a consultancy specialising in advising the private sector, on the problems it faces.

Buurtzorg battered as insurers refuse to pay

Buurtzorg, the Dutch foundation which is Europe’s fastest growing homecare operator, made a loss of €500,000 in 2013 on sales of €220m, thanks to insurers refusing to pay €9.5m bills. 2015 could also be a difficult year. we talk to Buurtzorg CEO Jos de Blok.

Five super-regions promise radical reform for Finland

The Finnish government, a coalition between the centre right and the social democrats, is proposing that all publicly paid for healthcare and care services should be procured by five new super regions. They would take over purchasing these services from the 320 municipalities who handle elderly and primary care and the 20 hospital regions who run acute care. But will the new regions actually take over the public nursing homes and hospitals or merely procurement of services? The move is seen as a potential bonanza for the private sector. Is this correct? We talk to Prof. Juhani Lehto about the odds on change.

Centene set to buy Ribera Salud

Centene, the US Medicaid specialist, is set to buy Spanish hospital Ribera Salud, the company behind the pioneering Alzira model in which a consortium of private operators run primary and secondary care for the public payor for a region of 250,000-300,000 people. It plans to then export Alzira to countries as varied as Latin America, the UK and even North America.

FREE BLOG Why spend billions on genetic tests if people won’t change their behaviour?

What is the point of spending billions on genetic tests, which warn patients of potential health conditions, if they pay no attention to the result? That is the question now being asked in countries like the UK, Denmark, Sweden, the Netherlands, Canada and Australia who, together, make up the most enthusiastic adherents thus far to evidence-based medicine.

Report: Will big medtech follow Medtronic into services?

Will big medtech follow the IBM path from product supplier to service provider? No other medtech company has expanded as fast as Medtronic into services. Here, we look at what the company offers, as well as its plans for the future. We also talk to one of its new customers, and look at how far the big imaging groups are willing and ready to move into the service arena. What impact will this have on existing service providers?

Patient records recruit B2C

The former Innovation Director at Belgium’s National Union of Health Insurance Funds, chronic disease management guru Jan van Emelen is trying to make patient records work better. Like Dr. Mohammad Al-Ubaydli of the UK’s Patients Know Best, van Emelen is creating records that are owned and controlled by patients, rather than clinicians - but, unlike his peer in the UK, van Emelen is recruiting on a business-to-consumer (B2C) basis with funding from big pharma. With 17,000 patients already enrolled, will his different approach pay off?

Interview: Stuart Fletcher, Chief Executive, Bupa

A year after Stuart “international growth opportunity” Fletcher took on the top job, where is he taking Bupa? The not-for-profit group offers insurance, hospitals, nursing homes, homecare and chronic disease management across the world. We talk to Fletcher about its recently-released results for 2012.

Find Us